Keep Me Logged In
Celgene's phase 2 study of its experimental Crohn's disease pill was published in The New England Journal of Medicine. Phase 3 is expected to start this year, reports CNBC's Meg Tirrell.
Got a confidential news tip? We want to hear from you.
Sign up for free newsletters and get more CNBC delivered to your inbox
© 2019 CNBC LLC. All Rights Reserved. A Division of NBCUniversal
Data is a real-time snapshot *Data is delayed at least 15 minutes. Global Business and Financial News, Stock Quotes, and Market Data and Analysis.
Data also provided by